Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial

M. Lambertini, F. Poggio, M. Bruzzone, B. Conte, C. Bighin, E. de Azambuja, M. Giuliano, M. De Laurentiis, F. Cognetti, A. Fabi, G. Bisagni, A. Durando, A. Turletti, Y. Urracci, O. Garrone, F. Puglisi, F. Montemurro, M. Ceppi, L. Del Mastro, on behalf of the GIM2 investigators

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences